Uttar Pradesh signed memorandums of understanding (MoUs) worth Rs 10,000 crore with pharmaceutical companies during the ‘Uttar Pradesh Pharma Conclave 1.0,’ inaugurated by Chief Minister Yogi Adityanath at Hotel Taj, Lucknow, on February 3.

Major investors included Arna Pharma and Biogenta Life Science, each committing Rs 1,250 crore, followed by Shukra Pharmaceuticals with Rs 737 crore, Walter Bushnell Enterprise' commitment of Rs 590 crore, Jhanvika Labs' Rs 553 crore investment, and several others contributing to the total investment. Addressing the gathering, CM Adityanath assured investors of transparent policies, and timely disbursement of incentives, highlighting UP’s transformation from a revenue-deficit state to a revenue-surplus one ready to contribute to a ‘Viksit Bharat.’ He emphasised that the conclave aims to establish the state as a hub for pharmaceutical manufacturing, innovation, AI, telemedicine, med tech, and clinical research.

The upcoming Lalitpur Bulk Drug Pharma Park, being developed on a hub-and-spoke model with advanced R&D facilities, along with future pharma parks in Bareilly and other districts, and a planned world-class pharma institute in Lucknow, are part of UP’s strategic vision to attract investment, strengthen infrastructure, and position itself as a global pharma and healthcare destination.